NTRK fusion testing in lung cancer – another reason to implement broad molecular profiling
With the emergence of a new class of targeted precision oncology therapies, NTRK fusions are increasingly becoming biomarkers that pathology laboratories can test for in FFPE tumor tissue.
sponsored by Thermo Fisher Scientific
With the emergence of a new class of targeted precision oncology therapies, NTRK fusions are increasingly becoming biomarkers that pathology laboratories can test for in FFPE tumor tissue. Although there are different testing options available such as IHC or FISH, NGS seems to be the preferred choice based on new guidelines. Register now to join us in discussing the pros and cons of different methods with the bigger picture in mind – the progress of precision oncology.
Learning Objectives of Webinar
- Why NTRK fusion testing is becoming important.
- What the different methods are including their pros and cons based on real data from lung cancer testing.
- How developments in precision oncology are changing not only cancer care, but also the way we should approach biomarker testing in our laboratories.
